Qamri Zahida, Pelletier Ronald, Foster Jamison, Kumar Sunil, Momani Hammam, Ware Kyle, Von Visger Jon, Satoskar Anjali, Nadasdy Tibor, Brodsky Sergey V
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Comprehensive Transplant Center, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Transpl Immunol. 2014 Aug;31(2):60-4. doi: 10.1016/j.trim.2014.06.006. Epub 2014 Jul 4.
Endothelial microparticles (EMPs) are membrane vesicles shed from endothelial cell in response to injury, activation or apoptosis. Kidney transplantation (KTx) is the treatment of choice for patients with end stage kidney disease (ESKD). The aim of this study was to analyze changes in EMP and serum creatinine (SCr) in patients following KTx.
Blood was periodically collected from patients before (pre-KTx) and after KTx for two months. EMPs were identified as CD31(+)/CD42b(-) microparticles and quantified by fluorescence-activated cell scanning.
This study included 213 KTx, 14 kidney/pancreas (KPTx) recipients and 60 healthy donors prior to donation. The recipients were divided into 5 groups based on the cause of ESKD. No differences in the quantity of circulating EMP were seen in the pre-KPTx or KTx recipient sera and healthy donor sera. Patients with ESKD secondary to diabetes mellitus, obstructive/inherited kidney disease and autoimmune disease had a decrease in both circulating EMP and SCr by day 60 after KTx.
Reduction in both circulating EMP and SCr was seen after kidney KTx in patients with selective ESKD.
内皮微粒(EMPs)是内皮细胞因损伤、激活或凋亡而脱落的膜囊泡。肾移植(KTx)是终末期肾病(ESKD)患者的首选治疗方法。本研究旨在分析肾移植患者术后内皮微粒(EMP)和血清肌酐(SCr)的变化。
在肾移植术前(KTx前)及术后两个月定期采集患者血液。内皮微粒被鉴定为CD31(+)/CD42b(-)微粒,并通过荧光激活细胞扫描进行定量分析。
本研究纳入了213例肾移植患者、14例肾/胰腺联合移植(KPTx)受者以及60例健康供者。根据ESKD病因将受者分为5组。在KPTx术前或肾移植受者血清与健康供者血清中,循环内皮微粒数量未见差异。继发于糖尿病、梗阻性/遗传性肾病和自身免疫性疾病的ESKD患者在肾移植术后60天时循环内皮微粒和血清肌酐均有所下降。
在部分ESKD患者肾移植术后,循环内皮微粒和血清肌酐均有所降低。